Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy
A snapshot of the stocks on the move, featuring Linius Technologies Ltd (ASX:LNU), Biotron Limited (ASX:BIT) and Elixir Energy (ASX:EXR).
Read More
Biotron Limited
Biotron Limited – Developing a new class of antiviral therapies
Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.
Spotlight Videos
Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy
A snapshot of the stocks on the move, featuring Linius Technologies Ltd (ASX:LNU), Biotron Limited (ASX:BIT) and Elixir Energy (ASX:EXR).
WATCH VIDEOAll Biotron Limited Content
News
Stocks That Tap The Disaster Zeitgeist
As is the norm, the speculative end of the market moves to its own rhythms and influences. In this vein, here are three ‘special situation’ stocks that plug into the topical anxieties of natural disasters, the coronavirus threat and the security of domestic gas supply.
Read More
Small Cap Biotech’s Under The Microscope
After some earlier positive trial results, the biotech sector is seeking treatment after some less than impressive results. But does value remain for investors?
Read More
